

# Resource Summary Report

Generated by [NIF](#) on Aug 18, 2026

## Drug Development Tools Qualification Programs

RRID:SCR\_003714

Type: Tool

### Proper Citation

Drug Development Tools Qualification Programs (RRID:SCR\_003714)

### Resource Information

**URL:**

<http://www.fda.gov/drugs/developmentapprovalprocess/drugdevelopmenttoolsqualificationprogram/d>

**Proper Citation:** Drug Development Tools Qualification Programs (RRID:SCR\_003714)

**Description:** To support Drug Development Tools development efforts, FDA established qualification programs for animal models for use under Animal Rule, biomarkers, and clinical outcome assessments. DDTs are methods, materials, or measures that have potential to facilitate drug development. Examples of DDTs may include, but are not limited to biomarker<sup>2</sup> used for clinical trial enrichment, clinical outcome assessment used to evaluate clinical benefit, and animal model used for efficacy testing of medical countermeasures under regulations commonly referred to as Animal Rule<sup>3</sup>.

**Abbreviations:** DDT Qualification Programs

**Synonyms:** Drug Development Tools (DDT) Qualification Programs

**Resource Type:** data or information resource, portal

**Keywords:** Drug<sup>1</sup> Development Tools, FDA established qualification programs, animal models for use under Animal Rule, gold standard

**Availability:** Public

**Resource Name:** Drug Development Tools Qualification Programs

**Resource ID:** SCR\_003714

**Alternate IDs:** nlx\_157888

**Record Creation Time:** 20220129T080220+0000

**Record Last Update:** 20260815T182803+0000

### Ratings and Alerts

No rating or validation information has been found for Drug Development Tools Qualification Programs.

No alerts have been found for Drug Development Tools Qualification Programs.

---

## Data and Source Information

**Source:** [SciCrunch Registry](#)

---

## Usage and Citation Metrics

We found 1 mentions in open access literature.

**Listed below are recent publications.** The full list is available at [NIF](#) .

Mol PGM, et al. (2018) Precision medicine in diabetes and diabetic kidney disease: Regulatory considerations. Diabetes, obesity & metabolism, 20 Suppl 3(Suppl Suppl 3), 19.